Immuno-Oncology 360° 2022 – March 16-18


Erin Newburn, PhD

Erin Newburn, PhD
Director, Field Applications Scientist
Personalis, Inc.

Wednesday, March 16 | 4:20 PM EDT

Personalis NeXT Platform

Enabling the future of precision oncology with comprehensive, unprecedented tumor profiling solutions for both tissue and liquid biopsy

  • Combining highly sensitive, exome-scale DNA and RNA sequencing with advanced analytics, ImmunoID NeXTTM provides a multidimensional view of the tumor and the tumor microenvironment from a single tumor sample preparation
  • A clinical case study in a cohort of late-stage melanoma patients demonstrating how the integration of neoantigen burden, HLA LOH, and Antigen Presentation Machinery (APM) mutational data formed a composite biomarker that more accurately predicted response to checkpoint blockade than other markers
  • In parallel, specimens may be processed using NeXT PersonalTM, an ultrasensitive tumor-informed liquid biopsy assay, designed to detect molecular residual disease and cancer recurrence at the earliest timepoints, with simultaneous variant tracking for additional insight into disease progression

Immuno-Oncology 360° 2022